NEW YORK (Reuters Health) – Rosuvastatin halves the rate of primary cardiovascular events in patients who have a high global cardiovascular risk profile, according to a post hoc…
NEW YORK (Reuters Health) – In patients with mixed dyslipidemia, fenofibric acid added to atorvastatin and ezetimibe results in improved lipid and non-lipid levels, according to a report…
NEW YORK (Reuters Health) – For patients with rheumatoid arthritis (RA), treatment with anti-tumor necrosis factor (TNF) agents appears to reduce their risk of cardiovascular events, including MI…
NEW YORK (Reuters Health) – Postmenopausal women treated for osteoporosis with the selective estrogen receptor modulator lasofoxifene have a reduced risk of coronary heart disease events, researchers report…
NEW YORK (Reuters Health) – In patients being treated for acute coronary syndromes (ACS), the loading dose of ticagrelor has a stronger inhibitory effect on platelets than does…
NEW YORK (Reuters Health) – Results of a small study indicate that transdermal testosterone improves functional capacity and other parameters in elderly women with chronic heart failure. Writing…
NEW YORK (Reuters Health) – Determining the low-density lipoprotein particle (LDL-p) concentration in women with HIV doesn’t seem to be worthwhile, as doing so adds little information beyond…
NEW YORK (Reuters Health) – Patients with NYHA class I or II heart failure benefit from spironolactone therapy as well as those with class III or IV HF,…
NEW YORK (Reuters Health) – The concern about proton pump inhibitors (PPIs) possibly interfering with the efficacy of clopidogrel may be misdirected, according to a new report. It…
NEW YORK (Reuters Health) – A consensus statement compiled by an international panel proposes that the level of platelet reactivity during antiplatelet therapy is a better measure of…